Author of

• 12592

  +

  P3.10 - Poster Session 3 - Chemotherapy (ID 210)

  • Event: WCLC 2013
  • Type: Poster Session
  • Track: Medical Oncology
  • Presentations: 2
  • Moderators:
  • Coordinates: 10/30/2013, 09:30 - 16:30, Exhibit Hall, Ground Level

  • 12642

    +

    P3.10-050 - Changes of pulmonary function after platinum based chemotherapy in small cell lung carcinoma (ID 3190)

    09:30 - 09:30  |  Author(s): W. Ban
    • Abstract

    Background
    Platinum based combination chemotherapy is the mainstay of treatment in patients with small cell lung cancer (SCLC). However, changes of pulmonary function after the chemotherapy in these patients have not been well characterized.

    Methods
    We reviewed the data from patients with SCLC treated with platinum based chemotherapy as a first-line treatment at St. Paul’s Hospital, The Catholic University of Korea, retrospectively. The basal clinical features and the outlook of changes in pulmonary function test (PFT) values of the patients before and after 2 or 3 cycles of chemotherapy were analyzed. Also, we surveyed factors affecting such pulmonary function changes.

    Results
    Eighteen patients were enrolled in this study. Baseline PFT values were measured and forced expiratory volume in 1 second (FEV1, 80.4%), forced vital capacity (FVC, 87.4%), and FEV1/FVC ratio (62.5%) showed an obstructive pattern. After the chemotherapy, overall spirometric values and lung volumes were not significantly changed, but diffusing capacity of the lung for carbon monoxide (DLCO) was significantly decreased ( p = 0.023). In multivariate analysis, peripheral tumor location was the only significant factor associated with DLCO reduction (HR 21.00; 95% CI 1.504-293.253; p=0.024). Patients with limited disease had a declining tendency of DLCO (p = 0.058) compared to the patients with extensive disease.

    Conclusion
    Platinum based chemotherapy could reduce DLCO in patients with SCLC. Tumor location was the only independent factor associated with DLCO reduction.

  • 12643

    +

    P3.10-051 - Change in Pulmonary function after chemotherapy is different between squamous cell carcinoma and adenocarcinoma of the lung (ID 3192)

    09:30 - 09:30  |  Author(s): W. Ban
    • Abstract

    Background
    Chemotherapy is a mainstay of therapy for lung cancer, and lung is an organ that manifests adverse reactions of chemotherapy. Also, owing to association with smoking, lung cancer is often seen in cases with compromised lung functions. Nevertheless, the baseline pulmonary functions and the manifestations of pulmonary function change after chemotherapy in patients with lung cancer have largely been unknown.

    Methods
    This retrospective study analyzed the data from patients who had been diagnosed as having non-small cell lung cancer (NSCLC) and treated at St. Paul’s Hospital, The Catholic University of Korea. The basal clinical features and the outlook of pulmonary function change of the patients before and after chemotherapy were analyzed by dividing them into two groups: adenocarcinoma (ADC) and squamous cell carcinoma (SCC).

    Results
    Sixty-four patients with stage III and IV NSCLC were included for analysis. Thirty-nine out of 64 patients had SCC. The SCC patient group had more males (p = 0.001), higher pack-years in smoking history (p < 0.001), and a higher rate of chronic obstructive pulmonary disease (COPD) as the baseline disorder at cancer diagnosis (p = 0.005). With respect to the baseline pulmonary functions, the SCC group showed significantly lower spirometric values of forced vital capacity (FVC; 79.4% vs 90.2%, p = 0,031), forced expiratory volume in 1 sec. (FEV1; 69.4% vs 90.5%, p=0.002), FEV1/FVC (59.2% vs 70.3%, p <0.001) and maximum midexpiratory flow rate (MMFR; 38% vs 60.2%, p=0.002). Variables associated with lung volume, TLC showed no differences between the SCC and ADC groups. However, residual volume (RV; 107.6% vs 84.6%, p = 0.012) and RV/total lung capacity (RV/TLC; 43% vs 34.8%, p=0.009) were significantly higher in the SCC group. The baseline DLCO level was significantly lower in the SCC group (82.8% vs 100.8%, p=0.013). After chemotherapy, pulmonary functions related to spirometry significantly improved while DLCO reductions were not significant in patients with SCC (-0.22%, p = 0.972). The ADC group revealed no change in variables relating to spirometry, but DLCO was reduced significantly (-16.6%, p = 0.021).

    Conclusion
    The baseline pulmonary functions and the changing pattern of pulmonary function after chemotherapy were different between these two groups. The pathogenesis and biological behavior of these respective histologic types of lung cancer would be attributable to these pulmonary functional alterations.